Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25709689 | 0.87 | MAPK1 (0.40) | MAPK1P2RX7 | |
| SCHEMBL23174245 | 0.85 | MAPK1 (0.38) | MAPK1P2RX7 | |
| SCHEMBL10290040 | 0.84 | MAPK1 (0.36) | MAPK1P2RX7 | |
| SCHEMBL253582 | 0.82 | P2RX7 (0.56) | MAPK1P2RX7 | |
| SCHEMBL21940425 | 0.81 | MAPK1 (0.33) | MAPK1P2RX7 | |
| SCHEMBL3263771 | 0.81 | — | — | |
| SCHEMBL31387313 | 0.80 | MAPK1 (0.51) | MAPK1P2RX7 | |
| SCHEMBL31387320 | 0.80 | MAPK1 (0.56) | MAPK1P2RX7 | |
| SCHEMBL12381903 | 0.79 | P2RX7 (0.58) | MAPK1P2RX7 | |
| SCHEMBL4857793 | 0.79 | P2RX7 (0.58) | MAPK1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 888 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115246787-A | Meta-disubstituted compound, preparation thereof and application thereof in preventing and treating mosquito and plant pathogenic bacteria | 吉林省达凯生物医药有限公司 | 2022-10-28 | — | — | CN | claimed |
| CN-113140792-B | High-energy-density lithium ion battery electrolyte and application thereof | 山东海容电源材料有限公司 | 2022-05-24 | — | — | CN | claimed |
| EP-4041730-B1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12624044-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12612408-B2 | Pyrazolone-fused pyrimidine compound, preparation method for same and applications thereof | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2026-04-28 | — | — | US | disclosed |
| EP-3870583-B1 | SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727940-A1 | DIHYDROPYRIMIDINE-2, 4 (1H, 3H) -DIONE-CONTAINING POLYCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREOF AND USE THEREOF | Linkcure Therapeutics (KY) | 2026-04-22 | — | — | EP | disclosed |
| US-12606568-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4720057-A2 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-1833806-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| US-20070155783-A1 | Substituted cyclohexyl and piperidinyl derivates as melanocortin-4 receptor modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-07-05 | — | — | US | disclosed |
| US-20070155783-A1 | Substituted cyclohexyl and piperidinyl derivates as melanocortin-4 receptor modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-07-05 | — | — | US | disclosed |
| US-20070155783-A1 | Substituted cyclohexyl and piperidinyl derivates as melanocortin-4 receptor modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-07-05 | — | — | US | disclosed |
| WO-2006114774-A2 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006064189-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| EP-1606278-A1 | SUBSTITUTED CYCLOHEXYL AND PIPERIDINYL DERIVATES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004083198-A1 | SUBSTITUTED CYCLOHEXYL AND PIPERIDINYL DERIVATES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2004-09-30 | — | — | WO | disclosed |
| EP-1460069-A1 | Substituted cyclohexyl and piperidinyl derivatives as melanocortin-4 receptor modulators | MyoContract Ltd. (CH) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | MAPK1 2997/4885P2RX7 1425/4885 |
| US-20070155783-A1 | Substituted cyclohexyl and piperidinyl derivates as melanocortin-4 receptor modulators | MC4R, MC5R, MC3R | MAPK1 2598/4885P2RX7 930/4885 |
| US-12624044-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCC1, SMARCA2 | MAPK1 2170/4885P2RX7 4108/4885 |
| US-12606568-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCD1, SMARCC1 | MAPK1 1413/4885P2RX7 4038/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | MAPK1 3215/4885P2RX7 1597/4885 |
| US-12612408-B2 | Pyrazolone-fused pyrimidine compound, preparation method for same and applications thereof | WEE1, WEE2, TK1 | MAPK1 64/4885P2RX7 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.